Ибупрофен.
Заказать уникальную курсовую работу- 19 19 страниц
- 41 + 41 источник
- Добавлена 29.02.2024
- Содержание
- Часть работы
- Список литературы
Пероральный уровень LD50 глюкозамина у крыс составляет >5000 мг/кг. Симптомы передозировки глюкозамином могут включать тошноту, рвоту, боль в животе и диарею (распространенные побочные эффекты этого препарата). Тяжелые и опасные для жизни реакции гиперчувствительности к глюкозамину могут возникать у пациентов с аллергией на моллюсков или астмой.4. Сочетание лекарственного средства и питательных веществ.Данные препараты разумно комбинировать при дегенративных заболеваниях суставов. Стратегия разработки лекарств для лечения ОА включает предотвращение катаболической деградации и апоптоза хондроцитов. Эти многоступенчатые процессы вовлекают множество медиаторов внутри- и внеклеточной коммуникации и несколько канонических путей внутриклеточной передачи сигналов, включая катаболические сигнальные пути, индуцируемые провоспалительными цитокинами, интерлейкином-1β (IL-1β) и фактором некроза опухоли-α (TNF-α), например ядерным фактором каппа-В (NF-kB)-опосредованная экспрессия провоспалительного фермента циклооксигеназы-2 (ЦОГ-2). Вмешательство, которое обеспечивает уменьшение боли, воспаления и/или скованности, связанных с ОА, может помочь улучшить подвижность суставов у пациентов с ОА.На данный момент уже существуют фиксированные комбинации препаратов: ибупрофен+куркумин; ибупрофен+глюкозамин. Данные вещества не усиливают токсичность и нежелательные явления друг друга и являются синергистами в плане противовоспалительного действия.Список использованной литературыRainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17:275–342. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44:489–506.Lloyd MD, Yevglevskis M, Lee GL, Wood PJ, Threadgill MD, Woodman TJ. α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013;52:220–230Jamali F, Mehvar R, Russell AS, Sattari S, Yakimets WW, Koo J. Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci. 1992;81:221–225.Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(−)-ibuprofen hydroxylation in vitro. Drug Metab Dispos. 2008;36:2513–2522.Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999;339 (Pt 3):607–614Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50 (Suppl):S423–S428.Blain H, Boileau C, Lapicque F, Nédélec E, Loeuille D, Guillaume C, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol. 2002;53:255–265.Rainsford KD. Discovery, mechanisms of action and safety of ibuprofen. Int J Clin Pract Suppl. 2003;135:3–8.Dawood MY, Khan-Dawood FS. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. Am J Obstet Gynecol. 2007;196:35e1–5.Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15.Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366.García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000–3006.García Rodríguez LA, González-Pérez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med. 2005;3:17.Bengmark S. Curcumin, an atoxic antioxidant and natural NF kappa B, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J Parenter Enteral Nutr. 2006;30(1):45–51Saja K, Babu MS, Karunagaran D, Sudhakaran PR. Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. Int Immunopharmacol. 2007;7(13):1659–1667.Shen CL, Smith BJ, Lo DF, Chyu MC, Dunn DM, Chen CH, Kwun IS. Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem. 2012;23:1367–77.Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009;58:899–908.Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A. Biological actions of curcumin on articular chondrocytes. Osteoarthr Cartil. 2010;18:141–9.Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005 Sep;41(13):1955–68. Singh SV, Hu X, Srivastava SK, et al. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis. 1998 Aug;19(8):1357–60.Kim J, Araki S, Kim D, et al. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-demethylhydrazine initiation. Carcinogenesis. 1998;19:81–5.Inano H, Onoda M, Inafuku N, et al. Potent preventive action of curcumin on radiation-induced initiation of mammary tumorigenesis in rats. Carcinogenesis. 2000 Oct;21(10):1835–41.Chuang SE, Kuo ML, Hsu CH, et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis. 2000 Feb;21(2):331–5Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005 Oct 15;11(20):7490–8.Jagetia GC, Aggarwal BB. “Spicing up” of the immune system by curcumin. J Clin Immunol. 2007 Jan;27(1):19–35Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001 Feb 1;61(3):1058–64.Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895–900.Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004 Oct 15;10(20):6847–54.Ogata T, Ideno Y, Akai M, Seichi A, Hagino H, Iwaya T, Doi T, Yamada K, Chen AZ, Li Y, Hayashi K. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clin Rheumatol. 2018 Sep;37(9):2479-2487. doi: 10.1007/s10067-018-4106-2. Epub 2018 Apr 30. PMID: 29713967; PMCID: PMC6097075.Cho, H.; Walker, A.; Williams, J.; Hasty, K.A. Study of osteoarthritis treatment with anti-inflammatory drugs: Cyclooxygenase-2 inhibitor and steroids. Biomed Res. Int. 2015, 2015.Aghazadeh-Habashi, A.; Kohan, M.H.; Asghar, W.; Jamali, F. Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. J. Pharm. Sci. 2014, 103, 760–767. [Google Scholar] [CrossRef] [PubMed]Li, Y.; Chen, L.; Liu, Y.; Zhang, Y.; Liang, Y.; Mei, Y. Anti-inflammatory effects in a mouse osteoarthritis model of a mixture of glucosamine and chitooligosaccharides produced by bi-enzyme single-step hydrolysis. Sci. Rep. 2018, 8, 5624. [Google Scholar] [CrossRef] [PubMed] [Green Version]Waly, N.E.; Refaiy, A.; Aborehab, N.M. IL-10 and TGF-beta: Roles in chondroprotective effects of Glucosamine in experimental Osteoarthritis? Pathophysiology 2017, 24, 45–49Cen, X.; Liu, Y.; Wang, S.; Yang, X.; Shi, Z.; Liang, X. Glucosamine oral administration as an adjunct to hyaluronic acid injection in treating temporomandibular joint osteoarthritis. Oral Dis. 2018, 24, 404–411Shen, J.; Li, S.; Chen, D. TGF-beta signaling and the development of osteoarthritis. Bone Res. 2014, 2Zhen, G.; Wen, C.; Jia, X.; Li, Y.; Crane, J.L.; Mears, S.C.; Askin, F.B.; Frassica, F.J.; Chang, W.; Yao, J.; et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 2013, 19, 704–712.Chiu, H.W.; Li, L.H.; Hsieh, C.Y.; Rao, Y.K.; Chen, F.H.; Chen, A.; Ka, S.M.; Hua, K.F. Glucosamine inhibits IL-1beta expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci. Rep. 2019, 9, 5603.Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005 Dec;13(12):1041-9. Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001 Sep;51(9):699-725.
1. Rainsford KD. Ibuprofen: pharmacology, efficacy and safety. Inflammopharmacology. 2009;17:275–342.
2. Pierce CA, Voss B. Efficacy and safety of ibuprofen and acetaminophen in children and adults: a meta-analysis and qualitative review. Ann Pharmacother. 2010;44:489–506.
3. Lloyd MD, Yevglevskis M, Lee GL, Wood PJ, Threadgill MD, Woodman TJ. α-Methylacyl-CoA racemase (AMACR): metabolic enzyme, drug metabolizer and cancer marker P504S. Prog Lipid Res. 2013;52:220–230
4. Jamali F, Mehvar R, Russell AS, Sattari S, Yakimets WW, Koo J. Human pharmacokinetics of ibuprofen enantiomers following different doses and formulations: intestinal chiral inversion. J Pharm Sci. 1992;81:221–225.
5. Chang SY, Li W, Traeger SC, Wang B, Cui D, Zhang H, et al. Confirmation that cytochrome P450 2C8 (CYP2C8) plays a minor role in (S)-(+)- and (R)-(−)-ibuprofen hydroxylation in vitro. Drug Metab Dispos. 2008;36:2513–2522.
6. Gierse JK, Koboldt CM, Walker MC, Seibert K, Isakson PC. Kinetic basis for selective inhibition of cyclo-oxygenases. Biochem J. 1999;339 (Pt 3):607–614
7. Smyth EM, Grosser T, Wang M, Yu Y, FitzGerald GA. Prostanoids in health and disease. J Lipid Res. 2009;50 (Suppl):S423–S428.
8. Blain H, Boileau C, Lapicque F, Nédélec E, Loeuille D, Guillaume C, et al. Limitation of the in vitro whole blood assay for predicting the COX selectivity of NSAIDs in clinical use. Br J Clin Pharmacol. 2002;53:255–265.
9. Rainsford KD. Discovery, mechanisms of action and safety of ibuprofen. Int J Clin Pract Suppl. 2003;135:3–8.
10. Dawood MY, Khan-Dawood FS. Clinical efficacy and differential inhibition of menstrual fluid prostaglandin F2alpha in a randomized, double-blind, crossover treatment with placebo, acetaminophen, and ibuprofen in primary dysmenorrhea. Am J Obstet Gynecol. 2007;196:35e1–5.
11. Bhala N, Emberson J, Merhi A, Abramson S, Arber N, Baron JA, et al. Coxib and traditional NSAID Trialists’ (CNT) Collaboration. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382:769–779.
12. Grosser T, Fries S, FitzGerald GA. Biological basis for the cardiovascular consequences of COX-2 inhibition: therapeutic challenges and opportunities. J Clin Invest. 2006;116:4–15.
13. Hippisley-Cox J, Coupland C. Risk of myocardial infarction in patients taking cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs: population based nested case-control analysis. BMJ. 2005;330:1366.
14. García Rodríguez LA, Varas-Lorenzo C, Maguire A, González-Pérez A. Nonsteroidal antiinflammatory drugs and the risk of myocardial infarction in the general population. Circulation. 2004;109:3000–3006.
15. García Rodríguez LA, González-Pérez A. Long-term use of non-steroidal anti-inflammatory drugs and the risk of myocardial infarction in the general population. BMC Med. 2005;3:17.
16. Bengmark S. Curcumin, an atoxic antioxidant and natural NF kappa B, cyclooxygenase-2, lipooxygenase, and inducible nitric oxide synthase inhibitor: a shield against acute and chronic diseases. J Parenter Enteral Nutr. 2006;30(1):45–51
17. Saja K, Babu MS, Karunagaran D, Sudhakaran PR. Anti-inflammatory effect of curcumin involves downregulation of MMP-9 in blood mononuclear cells. Int Immunopharmacol. 2007;7(13):1659–1667.
18. Shen CL, Smith BJ, Lo DF, Chyu MC, Dunn DM, Chen CH, Kwun IS. Dietary polyphenols and mechanisms of osteoarthritis. J Nutr Biochem. 2012;23:1367–77.
19. Mathy-Hartert M, Jacquemond-Collet I, Priem F, Sanchez C, Lambert C, Henrotin Y. Curcumin inhibits pro-inflammatory mediators and metalloproteinase-3 production by chondrocytes. Inflamm Res. 2009;58:899–908.
20. Henrotin Y, Clutterbuck AL, Allaway D, Lodwig EM, Harris P, Mathy-Hartert M, Shakibaei M, Mobasheri A. Biological actions of curcumin on articular chondrocytes. Osteoarthr Cartil. 2010;18:141–9.
21. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer. 2005 Sep;41(13):1955–68.
22. Singh SV, Hu X, Srivastava SK, et al. Mechanism of inhibition of benzo[a]pyrene-induced forestomach cancer in mice by dietary curcumin. Carcinogenesis. 1998 Aug;19(8):1357–60.
23. Kim J, Araki S, Kim D, et al. Chemopreventive effects of carotenoids and curcumins on mouse colon carcinogenesis after 1,2-demethylhydrazine initiation. Carcinogenesis. 1998;19:81–5.
24. Inano H, Onoda M, Inafuku N, et al. Potent preventive action of curcumin on radiation-induced initiation of mammary tumorigenesis in rats. Carcinogenesis. 2000 Oct;21(10):1835–41.
25. Chuang SE, Kuo ML, Hsu CH, et al. Curcumin-containing diet inhibits diethylnitrosamine-induced murine hepatocarcinogenesis. Carcinogenesis. 2000 Feb;21(2):331–5
26. Aggarwal BB, Shishodia S, Takada Y, et al. Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB pathway in breast cancer cells and inhibits lung metastasis of human breast cancer in nude mice. Clin Cancer Res. 2005 Oct 15;11(20):7490–8.
27. Jagetia GC, Aggarwal BB. “Spicing up” of the immune system by curcumin. J Clin Immunol. 2007 Jan;27(1):19–35
28. Ireson C, Orr S, Jones DJ, et al. Characterization of metabolites of the chemopreventive agent curcumin in human and rat hepatocytes and in the rat in vivo, and evaluation of their ability to inhibit phorbol ester-induced prostaglandin E2 production. Cancer Res. 2001 Feb 1;61(3):1058–64.
29. Cheng AL, Hsu CH, Lin JK, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001 Jul-Aug;21(4B):2895–900.
30. Sharma RA, Euden SA, Platton SL, et al. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004 Oct 15;10(20):6847–54.
31. Ogata T, Ideno Y, Akai M, Seichi A, Hagino H, Iwaya T, Doi T, Yamada K, Chen AZ, Li Y, Hayashi K. Effects of glucosamine in patients with osteoarthritis of the knee: a systematic review and meta-analysis. Clin Rheumatol. 2018 Sep;37(9):2479-2487. doi: 10.1007/s10067-018-4106-2. Epub 2018 Apr 30. PMID: 29713967; PMCID: PMC6097075.
32. Cho, H.; Walker, A.; Williams, J.; Hasty, K.A. Study of osteoarthritis treatment with anti-inflammatory drugs: Cyclooxygenase-2 inhibitor and steroids. Biomed Res. Int. 2015, 2015.
33. Aghazadeh-Habashi, A.; Kohan, M.H.; Asghar, W.; Jamali, F. Glucosamine dose/concentration-effect correlation in the rat with adjuvant arthritis. J. Pharm. Sci. 2014, 103, 760–767. [Google Scholar] [CrossRef] [PubMed]
34. Li, Y.; Chen, L.; Liu, Y.; Zhang, Y.; Liang, Y.; Mei, Y. Anti-inflammatory effects in a mouse osteoarthritis model of a mixture of glucosamine and chitooligosaccharides produced by bi-enzyme single-step hydrolysis. Sci. Rep. 2018, 8, 5624. [Google Scholar] [CrossRef] [PubMed] [Green Version]
35. Waly, N.E.; Refaiy, A.; Aborehab, N.M. IL-10 and TGF-beta: Roles in chondroprotective effects of Glucosamine in experimental Osteoarthritis? Pathophysiology 2017, 24, 45–49
36. Cen, X.; Liu, Y.; Wang, S.; Yang, X.; Shi, Z.; Liang, X. Glucosamine oral administration as an adjunct to hyaluronic acid injection in treating temporomandibular joint osteoarthritis. Oral Dis. 2018, 24, 404–411
37. Shen, J.; Li, S.; Chen, D. TGF-beta signaling and the development of osteoarthritis. Bone Res. 2014, 2
38. Zhen, G.; Wen, C.; Jia, X.; Li, Y.; Crane, J.L.; Mears, S.C.; Askin, F.B.; Frassica, F.J.; Chang, W.; Yao, J.; et al. Inhibition of TGF-beta signaling in mesenchymal stem cells of subchondral bone attenuates osteoarthritis. Nat. Med. 2013, 19, 704–712.
39. Chiu, H.W.; Li, L.H.; Hsieh, C.Y.; Rao, Y.K.; Chen, F.H.; Chen, A.; Ka, S.M.; Hua, K.F. Glucosamine inhibits IL-1beta expression by preserving mitochondrial integrity and disrupting assembly of the NLRP3 inflammasome. Sci. Rep. 2019, 9, 5603.
40. Persiani S, Roda E, Rovati LC, Locatelli M, Giacovelli G, Roda A: Glucosamine oral bioavailability and plasma pharmacokinetics after increasing doses of crystalline glucosamine sulfate in man. Osteoarthritis Cartilage. 2005 Dec;13(12):1041-9.
41. Setnikar I, Rovati LC: Absorption, distribution, metabolism and excretion of glucosamine sulfate. A review. Arzneimittelforschung. 2001 Sep;51(9):699-725.